MCID: PNV001
MIFTS: 48

Panuveitis

Categories: Eye diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Panuveitis

MalaCards integrated aliases for Panuveitis:

Name: Panuveitis 12 20 58 54 44 15 17 70
Diffuse Uveitis 12 20
Total Uveitis 20 58
Inflammation of the Whole Uveal Tract 20

Characteristics:

Orphanet epidemiological data:

58
panuveitis
Inheritance: Not applicable; Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:12030
ICD9CM 34 360.12
MeSH 44 D015864
NCIt 50 C84989
SNOMED-CT 67 75614007
ICD10 32 H44.11
ICD10 via Orphanet 33 H44.1
UMLS via Orphanet 71 C0030343
Orphanet 58 ORPHA280898
UMLS 70 C0030343

Summaries for Panuveitis

GARD : 20 Panuveitis is inflammation of all layers of the uvea of the eye, which includes the iris, ciliary body, and choroid. These make up the middle layer of the eye. The condition can also affect the lens, retina, optic nerve, and vitreous, causing reduced vision or blindness. Signs and symptoms may include eye redness and pain; blurring; light sensitivity; decreased vision; and seeing floaters. It can last for a short time or can occur chronically. Severe cases may recur many times. In many cases the specific cause is unknown, but in some cases it occurs in association with other eye conditions, or with another condition or infection that also affects other body parts. Early treatment is needed and may include eye drops to reduce inflammation and pain; and/or oral medications or injections in severe cases.

MalaCards based summary : Panuveitis, also known as diffuse uveitis, is related to vogt-koyanagi-harada disease and sympathetic ophthalmia. An important gene associated with Panuveitis is UACA (Uveal Autoantigen With Coiled-Coil Domains And Ankyrin Repeats), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Hormones and Hormone Antagonists have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and retina, and related phenotype is endocrine/exocrine gland.

Disease Ontology : 12 An uveitis that is characterized by inflammation of all layers of the uvea (middle layer) of the eye, which includes the iris, ciliary body, and choroid.

Related Diseases for Panuveitis

Diseases in the Panuveitis family:

Infectious Panuveitis Systemic Diseases with Panuveitis

Diseases related to Panuveitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 880)
# Related Disease Score Top Affiliating Genes
1 vogt-koyanagi-harada disease 32.0 IL17A IL10 IFNA2 HLA-DRB1 HLA-DQB1
2 sympathetic ophthalmia 31.9 TNF RBP3 IL10 HLA-DRB1
3 multifocal choroiditis 31.4 TNF IL10
4 pars planitis 31.1 RBP3 HLA-DRB1 CCR6
5 uveitis 31.1 TNF SAG RBP3 IL6 IL17A IL10
6 macular retinal edema 30.9 TNF IL6 ACE
7 punctate inner choroidopathy 30.8 TNF IL10
8 intermediate uveitis 30.7 TNF IL6 IL10 HLA-DRB1 CCR6
9 posterior uveitis 30.7 TNF SAG RBP3 IL6 ICOSLG CCR6
10 choroiditis 30.6 TNF SAG RBP3 IL17A IL10 CD4
11 scleritis 30.6 TNF CRP CCR6
12 neuroretinitis 30.6 SAG CRP CD4 ACE
13 neurosyphilis 30.6 IL17A IL10
14 neuritis 30.6 TNF IL6 IL10 HLA-DRB1
15 endophthalmitis 30.5 TNF SAG IL6 CRP
16 vasculitis 30.5 TNF SERPINA3 IL6 IL17A IFNA2 CRP
17 histoplasmosis 30.5 TNF HLA-DRB1 CD4 CCR6
18 retinal vasculitis 30.5 TNF SAG RBP3 CD4 CCR6 ACE
19 toxoplasmosis 30.5 TNF IL6 IL10 HLA-DQB1
20 ocular tuberculosis 30.4 CD4 ACE
21 optic neuritis 30.4 TNF IL6 IL10 HLA-DRB1 HLA-DQB1
22 cytomegalovirus retinitis 30.3 TNF IL10 HLA-DRB1 HLA-DQB1 CD4
23 conjunctivitis 30.3 TNF IL6 IL10
24 retinal vascular disease 30.3 TNF IL6 ACE
25 aseptic meningitis 30.2 TNF IL10 CRP
26 leptospirosis 30.2 TNF IL6 IL10 CRP
27 hypopyon 30.1 TNF RBP3 IL6 IL17A IL10 CRP
28 asymptomatic neurosyphilis 30.1 IL17A CD4
29 relapsing polychondritis 30.1 IL6 IL17A IL10 CRP
30 cat-scratch disease 30.1 CRP CD4 ACE
31 guillain-barre syndrome 30.1 TNF IL17A HLA-DRB1 HLA-DQB1
32 cutaneous leishmaniasis 30.0 TNF IL6 IL17A IL10
33 ophthalmomyiasis 30.0 SAG RBP3 CD4
34 cardiogenic shock 30.0 TNF IL6
35 meningitis 30.0 TNF IL6 IL17A IL10 CRP
36 herpes zoster 30.0 TNF IL10 IFNA2 ICOSLG HLA-DRB1 CD4
37 arachnoiditis 30.0 TNF CRP CD4
38 pulmonary tuberculosis 30.0 TNF IL6 IL10 HLA-DRB1 HLA-DQB1
39 miliary tuberculosis 30.0 TNF CRP CD4
40 interstitial nephritis 30.0 ICOSLG CRP CCR6 ACE
41 mature t-cell and nk-cell lymphoma 30.0 ICOSLG CD4 CCR6
42 cryptogenic organizing pneumonia 30.0 TNF CRP CD4
43 histiocytosis 30.0 TNF SERPINA3 IL17A CCR6
44 birdshot chorioretinopathy 30.0 RBP3 IL17A ERAP2 ERAP1 CCR6
45 igg4-related disease 30.0 ICOSLG CRP CCR6
46 peritonitis 30.0 TNF IL6 IL10 CRP
47 juvenile rheumatoid arthritis 30.0 TNF IL6 IL10 HLA-DRB1 HLA-DQB1 CRP
48 pustulosis of palm and sole 29.9 TNF IL17A CRP CCR6
49 multiple cranial nerve palsy 29.9 CRP ACE
50 cheilitis 29.9 TNF ERAP1 CD4 CCR6

Graphical network of the top 20 diseases related to Panuveitis:



Diseases related to Panuveitis

Symptoms & Phenotypes for Panuveitis

MGI Mouse Phenotypes related to Panuveitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.32 ACE CD4 ERAP1 HLA-DQB1 IL10 IL17A

Drugs & Therapeutics for Panuveitis

Drugs for Panuveitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 48)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Hormones Phase 4
2 Hormone Antagonists Phase 4
3 Adrenocorticotropic Hormone Phase 4
4 Melanocyte-Stimulating Hormones Phase 4
5 beta-Endorphin Phase 4
6
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
7
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
8
Difluprednate Approved Phase 3 23674-86-4 443936
9
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 3 67-73-2 6215
10
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
11
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
12
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
13
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
14
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
15
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
16
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
17
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
18 Immunosuppressive Agents Phase 3
19 Triamcinolone diacetate Phase 3
20 Triamcinolone hexacetonide Phase 3
21 triamcinolone acetonide Phase 3
22 glucocorticoids Phase 3
23 Anti-Inflammatory Agents Phase 3
24 Antirheumatic Agents Phase 3
25 Antineoplastic Agents, Hormonal Phase 3
26 Dermatologic Agents Phase 3
27 Anti-Infective Agents Phase 3
28 Antifungal Agents Phase 3
29 Methylprednisolone Acetate Phase 3
30 Interferon alpha-2 Phase 3
31 interferons Phase 3
32 Antiviral Agents Phase 3
33 Calcineurin Inhibitors Phase 3
34 Cyclosporins Phase 3
35 Interferon-alpha Phase 3
36 Pharmaceutical Solutions Phase 3
37
Adalimumab Approved, Experimental Phase 2 331731-18-1 16219006
38
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
39
Methotrexate Approved Phase 1, Phase 2 1959-05-2, 59-05-2 126941
40
Levoleucovorin Approved, Investigational Phase 1, Phase 2 68538-85-2 149436
41
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
42 Anti-Bacterial Agents Phase 2
43 Antibiotics, Antitubercular Phase 2
44 Folic Acid Antagonists Phase 1, Phase 2
45 Vitamin B9 Phase 1, Phase 2
46 Vitamin B Complex Phase 1, Phase 2
47 Folate Phase 1, Phase 2
48 Antimetabolites Phase 1, Phase 2

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Open Label Pilot Study to Explore the Efficacy and Safety of Acthar Gel in Subjects With Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis (NIPPU) Terminated NCT03656692 Phase 4 Acthar Gel
2 A 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet¿s Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy Completed NCT00995709 Phase 3 AIN457;AIN457;Placebo
3 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients Completed NCT01138657 Phase 3 Prednisone;Placebo
4 A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis Completed NCT01148225 Phase 3 adalimumab
5 A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Inactive Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients Completed NCT01124838 Phase 3 Adalimumab;Prednisone;Placebo
6 Phase 3 Open-Labeled Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Severe Anterior Uveitis (Including Panuveitis). Completed NCT00407056 Phase 3 Difluprednate Ophthalmic Emulsion
7 Phase 3 Confirmatory Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Anterior Uveitis (Including Panuveitis). Completed NCT00406887 Phase 3 Difluprednate Ophthalmic Emulsion
8 A Multi-center, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye Completed NCT02746991 Phase 3 Sham Injection;FAI Insert
9 A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects With Macular Edema Associated With Non-infectious Uveitis Completed NCT02595398 Phase 3 4mg CLS-TA Suprachoriodal Injection;Sham Procedure
10 A Double-Masked, Placebo-Controlled, Multi-Center, Parallel-Group, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Clinically Quiescent Sight Threatening, Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Completed NCT00404742 Phase 3 Placebo;LX211;LX211;LX211
11 A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Completed NCT00404612 Phase 3 Placebo;LX211;LX211;LX211
12 A Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Anterior Uveitis Completed NCT00404885 Phase 3 Placebo;LX211;LX211;LX211
13 Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet's Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB) Completed NCT00167583 Phase 3 Cyclosporin A;Interferon-alpha2a
14 Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients With Non-Infectious Uveitis Completed NCT03097315 Phase 3
15 A 38-week Extension to a 24-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis Terminated NCT01090310 Phase 3 AIN457;Placebo
16 A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis. Terminated NCT01032915 Phase 3 Placebo
17 A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study) Terminated NCT01095250 Phase 3 AIN457;AIN457;AIN457;Placebo
18 A 38-week Extension to a 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet's Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy (SHIELD Study) Terminated NCT01093846 Phase 3 AIN457;AIN457;Placebo AIN457
19 A 34-week Extension to a 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior, or Panuveitis Requiring Immunosuppression (INSURE Study) Withdrawn NCT01103024 Phase 3
20 A Multicenter, Open-label Study to Evaluate the Long Term Clinical Use of Treatment With AIN457 in Patients Completing Clinical Trials Investigating AIN457 for the Treatment of Non-infectious Intermediate, Posterior or Panuveitis Withdrawn NCT01327664 Phase 3
21 Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study Unknown status NCT01717170 Phase 1, Phase 2 Tocilizumab
22 A Randomized, Masked, Multicenter Study to Assess the Safety and Efficacy of CLS-TA, Triamcinolone Acetonide Injectable Suspension in the Treatment of Subjects With Macular Edema Following Uveitis Completed NCT02255032 Phase 2 4 mg CLS-TA;0.8 mg CLS-TA
23 Open-Label, Safety and Tolerability Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle in Subjects With Non-Infectious Uveitis Completed NCT01789320 Phase 1, Phase 2 triamcinolone acetonide (Triesence®)
24 A Randomized, Active-controlled, Open-label, Multicenter proof-of Concept Study of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, Posterior-, or Panuveitis Requiring Systemic Immunosuppressive Therapy Completed NCT01526889 Phase 2 LFG316;Conventional Therapy
25 A Multicenter, Single Sequence, Open-label Study to Assess the Tolerability, Safety, and Efficacy of 2 Weeks Oral AEB071 300 mg Twice Daily, Followed by 6 Weeks AEB071 200 mg Twice Daily in the Treatment of Patients With Macular Edema Associated With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis Completed NCT00615693 Phase 2 AEB071
26 Phase 2a Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Anterior Uveitis (Inluding Iritis, Cyclitis, Iridocyclitis, and Panuveitis). Completed NCT00405496 Phase 2 Difluprednate Ophthalmic Emulsion
27 A Phase I/II, Open-label, Multicentre, Dose Escalation Study Assessing Safety/Tolerability of pEYS606 When Administered by Electrotransfer (ET) in Ciliary Muscle of Patients With Non-infectious Posterior, Intermediate or Panuveitis Recruiting NCT03308045 Phase 1, Phase 2
28 Adalimumab in Combination With Methotrexate for the Treatment of Non-infectious Panuveitis in Chinese Children Recruiting NCT04588818 Phase 2 Adalimumab plus Methotrexate
29 Sirolimus as a Therapeutic Approach for Uveitis: A Phase 2, Open-label, Randomized Study to Assess the Safety, Tolerability, and Bioactivity of Two Doses of Intravitreal Injection of Sirolimus in Patients With Non-infectious Uveitis Recruiting NCT01280669 Phase 2 Intravitreal injection 440mcg;Intravitreal injection of sirolimus 880mcg
30 Treatment of Non-infectious Panuveitis, Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate Terminated NCT01314417 Phase 1, Phase 2 Methotrexate
31 A Phase I/IIa Study of the Treatment of None-Infectious Anterior, Intermediate, Posterior and Panuveitis, With the Use of Dexamethasone Delivered by a Iontophoresis Device Withdrawn NCT00499551 Phase 1, Phase 2
32 A Multicenter, Randomized, Active-controlled Study to Assess the Safety, Tolerability, and Efficacy of FTY720 in Patients With Acute, Noninfectious Intermediate, Posterior and Pan Uveitis Withdrawn NCT01791192 Phase 2 FTY720;Oral Corticosteroid
33 Pilot Study of a Fluocinolone Acetonide Intravitreal Insert (FA-i) to Treat Intermediate-, Posterior-, or Panuveitis Completed NCT01781936 Phase 1 Fluocinolone Acetonide
34 A Phase 1, Open-label, Randomized Clinical Study to Assess the Safety, Tolerability and Bioactivity of Intravitreal and Subconjunctival Injection of Sirolimus in Patients With Non-infectious Uveitis Completed NCT00908466 Phase 1 Sirolimus (rapamycin);Sirolimus (rapamycin)
35 Quality of Life and Visual Function in Uveitis Patients Unknown status NCT00407316
36 Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients According to the Standard for "Re-examination of New Drugs" Completed NCT03339102
37 Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice -HOPE Completed NCT03155243
38 MAGNOLIA: Multi-Center, Non-Interventional Extension Study of the Safety and Efficacy of CLS-TA for the Treatment of Macular Edema Associated With Non-Infectious Uveitis Completed NCT02952001 4mg CLS-TA Suprachoriodal Injection;Sham procedure
39 HUMIRA® Special Investigation (Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis) Completed NCT02916017
40 Pathogen Detection in Infectious Uveitis in China Recruiting NCT04521673
41 Ocular Sarcoidosis Open Label Trial of ACTHAR Gel Recruiting NCT02725177 Repository Corticotropin Injection;Repository Corticotropin Injection -Treatment Extension
42 Pilot Project: The Amplicon and Metatranscriptomic Next-generation Sequencing of Samples From Intra and Extra-intestinal Microbiome in Non-infectious Uveitis Patients to Decipher Possibility Uveitis Pathogenesis Not yet recruiting NCT04126850

Search NIH Clinical Center for Panuveitis

Cochrane evidence based reviews: panuveitis

Genetic Tests for Panuveitis

Anatomical Context for Panuveitis

MalaCards organs/tissues related to Panuveitis:

40
Eye, Skin, Retina, Heart, Lung, Bone, Thyroid

Publications for Panuveitis

Articles related to Panuveitis:

(show top 50) (show all 1522)
# Title Authors PMID Year
1
Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study. 54 61
9713053 1998
2
A case of panuveitis and retinal vasculitis associated with pembrolizumab therapy for metastatic lung cancer. 61
33796799 2021
3
Cytomegalovirus retinitis following dexamethasone intravitreal implant. 61
33732951 2021
4
Multimodal imaging in infectious and noninfectious intermediate, posterior and panuveitis. 61
33710009 2021
5
Epidemiology of pediatric uveitis and associated systemic diseases. 61
33794945 2021
6
Characteristics, evolution, and outcome of patients with non-infectious uveitis referred for rheumatologic assessment and management: an Egyptian multicenter retrospective study. 61
32876781 2021
7
Ponatinib Inducing a Panuveitis with Choroidal Effusions and Neurosensory Retinal Detachment in a Patient with Chronic Myeloid Leukaemia. 61
33661078 2021
8
Intravenous methylprednisolone induces rapid improvement in non-infectious uveitis: a multicentre study of 112 patients. 61
33666160 2021
9
Distinct clinical characteristics of pediatric Behçet's syndrome: A study from a referral center in China. 61
33627024 2021
10
Intraocular leucocyte subpopulations analysis by multiparametric flow cytometry in human uveitis. 61
32424059 2021
11
Long-term Management of Panuveitis and Choroidal Mass Associated with Rosai Dorfman Disease with Pegylated Interferon. 61
33683183 2021
12
Epidemiology of 2000 Chinese uveitis patients from Northeast China. 61
32424058 2021
13
Post COVID-19 Ophthalmic Manifestations in an Asian Indian Male. 61
33733987 2021
14
Aetiology and clinical characteristics of uveitic glaucoma in Turkish patients. 61
33730317 2021
15
Atypical Sympathetic Ophthalmia Presenting with Ocular Pain Associated with Posterior Scleral Involvement. 61
33734929 2021
16
Granulocyte Colony Stimulating Factor-induced Immune Recovery Uveitis Associated with Cytomegalovirus Retinitis in the Setting of Good Syndrome. 61
33561367 2021
17
Clinical Characteristics of Uveitis in Patients with Psoriasis in Korea: A Retrospective Multicenter Case Series. 61
33307622 2021
18
Tubulointerstitial nephritis and uveitis syndrome: a systematic review. 61
33561271 2021
19
Ocular Co-infection with Mycobacterium Tuberculosis and Toxoplasma Gondii in an Immunocompetent Patient - A Case Report. 61
33544637 2021
20
Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitis-Report 2: Guidelines for Initiating Antitubercular Therapy in Anterior Uveitis, Intermediate Uveitis, Panuveitis, and Retinal Vasculitis. 61
32603726 2021
21
Prognosis of Ocular Tuberculosis Following Long-Term Antitubercular Therapy. 61
33524301 2021
22
Stalagmite-like pre-retinal deposits in the optical coherence tomography of two vitrectomy patients with panuveitis. 61
33610383 2021
23
Coronavirus Disease 2019-Associated Ocular Neuropathy With Panuveitis: A Case Report. 61
33331870 2021
24
Vogt-Koyanagi-Harada disease is always bilateral: reports of unilateral cases failed to use choroidal investigations showing subclinical involvement of the fellow eye. 61
33559795 2021
25
A novel mutation in early-onset sarcoidosis/Blau syndrome: an association with Propionibacterium acnes. 61
33602264 2021
26
Evaluation of Lamina Cribrosa by Using Enhanced Depth Imaging Optical Coherence Tomography in Ocular Sarcoidosis during Quiescent Phase. 61
33534381 2021
27
Epidemiology of Uveitis in a tertiary care centre in Portugal. 61
33593242 2021
28
[Ocular manifestations of Behçet's disease]. 61
33380351 2021
29
The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis. 61
33527798 2021
30
Panuveitis in a patient with active Crohn's disease. 61
33541992 2021
31
Tuberculous Scleritis and Multidrug Resistance. 61
33416427 2021
32
Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. 61
33124565 2021
33
Uveitis as an Open Window to Systemic Inflammatory Diseases. 61
33466638 2021
34
Multimodal Imaging of Parry Romberg Syndrome-associated Panuveitis: A Case Report and Review of Literature. 61
31577463 2021
35
Prevalence and clinical features of systemic diseases in Chinese patients with uveitis. 61
32188681 2021
36
Endogenous Endophthalmitis Caused by Group B Streptococcus in a Healthy, Term Neonate. 61
33492072 2021
37
Endothelin-1 Serum Concentration in Pediatric Chronic Idiopathic Uveitis. 61
33469261 2021
38
Role of Ocular Imaging in Diagnosis and Determining Response to Therapeutic Interventions in Posterior and Panuveitis. 61
33512829 2021
39
Tocilizumab as an Effective Treatment Option in Children with Refractory Intermediate and Panuveitis. 61
32058831 2021
40
Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes. 61
32815757 2021
41
Characteristics and phenotype heterogeneity in late-onset Behçet's syndrome: a cohort from a referral center in China. 61
33411142 2021
42
Clinical and laboratory characteristics of ocular syphilis and neurosyphilis among individuals with and without HIV infection. 61
32220852 2021
43
Syphilitic Outer Retinopathy: A Masquerading Diagnosis Revealed After Steroid-Induced Progression to Panuveitis. 61
33323897 2020
44
Recurrent panuveitis after initial treatment of endophthalmitis secondary to intravitreal anti-vascular endothelial growth factor. 61
32827449 2020
45
Responsiveness of Vision-Specific and General Quality of Life Metrics to Ocular and Systemic Events in Patients with Uveitis. 61
32717341 2020
46
Efficacy and safety of immunomodulatory drugs in patients with non-infectious intermediate and posterior uveitis, panuveitis and macular edema: A systematic literature review. 61
33065425 2020
47
Ocular sarcoidosis: clinical experience and recent pathogenetic and therapeutic advancements. 61
32740881 2020
48
Choroidal nonperfusion on optical coherence tomography angiography in a case of unilateral posterior segment ocular sarcoidosis misdiagnosed as MEWDS. 61
33024892 2020
49
The first investigation on differences in the effectiveness of mycophenolate mofetil and azathioprine antimetabolites determined in Polish patients treated for non-infectious uveitis. 61
33356073 2020
50
Nontuberculous mycobacterial endophthalmitis: case series and review of literature. 61
33228593 2020

Variations for Panuveitis

Expression for Panuveitis

Search GEO for disease gene expression data for Panuveitis.

Pathways for Panuveitis

Pathways related to Panuveitis according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 TNF SERPINA3 IL6 IL17A IL10 IFNA2
2
Show member pathways
13.3 TNF IL6 IL17A IL10 IFNA2 HLA-DRB1
3 12.76 TNF IL6 IFNA2 HLA-DRB1 HLA-DQB1
4
Show member pathways
12.57 TNF IL6 IL17A IL10 CD4
5
Show member pathways
12.56 TNF IL10 ICOSLG HLA-DRB1 HLA-DQB1 CD4
6
Show member pathways
12.55 TNF IL6 IL17A IL10 CD4
7
Show member pathways
12.51 TNF IL6 IL17A IL10 HLA-DRB1 HLA-DQB1
8
Show member pathways
12.35 ICOSLG HLA-DRB1 HLA-DQB1 CD4
9
Show member pathways
12.35 TNF IL6 IL17A IL10 IFNA2 ICOSLG
10
Show member pathways
12.29 TNF SERPINA3 IL6 CRP
11
Show member pathways
12.29 TNF IL6 IL10 CCR6
12 12.29 TNF IL6 HLA-DRB1 HLA-DQB1 CD4
13
Show member pathways
12.24 TNF IL6 IL17A IL10 IFNA2
14
Show member pathways
12.23 TNF IL10 HLA-DRB1 HLA-DQB1
15
Show member pathways
12.19 ICOSLG HLA-DRB1 HLA-DQB1 CD4
16 12.1 TNF IL6 IL10 IFNA2 HLA-DRB1 HLA-DQB1
17 12.09 ICOSLG HLA-DRB1 HLA-DQB1 CD4
18 12.05 TNF IL6 IL10 CD4
19 11.96 TNF IL6 IL10 IFNA2 CD4
20 11.92 TNF IL6 IL17A IL10
21 11.87 TNF IL6 HLA-DRB1 HLA-DQB1 CD4
22 11.84 SERPINA3 SAG RBP3 CRP
23 11.82 TNF IL6 IL17A HLA-DRB1 HLA-DQB1
24
Show member pathways
11.73 HLA-DRB1 HLA-DQB1 CD4
25 11.72 TNF IL6 IL10
26 11.71 TNF IL17A IL10 CD4 CCR6
27 11.69 HLA-DRB1 HLA-DQB1 CD4
28
Show member pathways
11.6 TNF IL6 IL17A IL10 CD4
29 11.52 TNF IL6 IL10
30 11.52 TNF IL6 IL10 IFNA2 CD4
31 11.5 TNF IL6 IL10
32 11.37 TNF IL6 IL10 ICOSLG CCR6
33 11.35 TNF IL6 IL10
34 11.31 TNF IL6 IL10
35 11.26 TNF IL6 IL17A
36 10.99 TNF IL6 CRP
37 10.48 TNF IL6 IL10 HLA-DRB1 CD4

GO Terms for Panuveitis

Cellular components related to Panuveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.93 UACA TNF SERPINA3 RBP3 IL6 IL17A
2 extracellular space GO:0005615 9.7 TNF SERPINA3 RBP3 IL6 IL17A IL10
3 external side of plasma membrane GO:0009897 9.17 TNF IL17A ICOSLG HLA-DRB1 CD4 CCR6

Biological processes related to Panuveitis according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.2 SAG IL6 IL10 ICOSLG HLA-DRB1 ERAP2
2 positive regulation of transcription, DNA-templated GO:0045893 10.07 TNF IL6 IL10 IFNA2 HLA-DRB1 CD4
3 immune system process GO:0002376 10.02 IL17A ICOSLG HLA-DRB1 HLA-DQB1 ERAP2 ERAP1
4 inflammatory response GO:0006954 9.88 TNF SERPINA3 IL6 IL17A IFNA2 CRP
5 T cell receptor signaling pathway GO:0050852 9.86 ICOSLG HLA-DRB1 HLA-DQB1 CD4
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 TNF IL6 IFNA2
7 regulation of blood pressure GO:0008217 9.79 ERAP2 ERAP1 ACE
8 response to glucocorticoid GO:0051384 9.79 TNF IL6 IL10
9 positive regulation of interleukin-1 beta production GO:0032731 9.76 TNF IL6 IL17A
10 defense response to Gram-positive bacterium GO:0050830 9.76 TNF IL6 IL17A CRP
11 cytokine-mediated signaling pathway GO:0019221 9.73 TNF IL6 IL17A IL10 IFNA2 CD4
12 acute-phase response GO:0006953 9.71 SERPINA3 IL6 CRP
13 positive regulation of JAK-STAT cascade GO:0046427 9.69 TNF IL6 IL10
14 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.67 ERAP2 ERAP1 ACE
15 antigen processing and presentation of endogenous peptide antigen via MHC class I GO:0019885 9.63 ERAP2 ERAP1
16 neutrophil mediated immunity GO:0002446 9.63 IL6 ACE
17 humoral immune response GO:0006959 9.62 TNF IL6 IFNA2 CCR6
18 endothelial cell apoptotic process GO:0072577 9.61 TNF IL10
19 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.61 TNF IL6 IL17A
20 vascular endothelial growth factor production GO:0010573 9.6 TNF IL6
21 negative regulation of cytokine production involved in immune response GO:0002719 9.58 TNF IL10
22 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.57 HLA-DRB1 HLA-DQB1
23 immune response GO:0006955 9.56 TNF IL6 IL17A IL10 HLA-DRB1 HLA-DQB1
24 peptide catabolic process GO:0043171 9.54 ERAP2 ERAP1 ACE
25 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.52 HLA-DRB1 HLA-DQB1
26 negative regulation of lipid storage GO:0010888 9.33 TNF IL6 CRP
27 adaptive immune response GO:0002250 9.23 IL17A IFNA2 ICOSLG HLA-DRB1 HLA-DQB1 ERAP2

Molecular functions related to Panuveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 9.16 HLA-DRB1 HLA-DQB1
2 cytokine activity GO:0005125 9.02 TNF IL6 IL17A IL10 IFNA2
3 interleukin-6 receptor binding GO:0005138 8.96 IL6 ERAP1

Sources for Panuveitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....